J&J Q3 sales $25.4B, up 5.9%; GAAP EPS $0.09 (-95.8%) on $5.78B other expense; adj EPS $2.59 (-7.5%)

JOHNSON & JOHNSON

Q3 worldwide sales $25,399M vs $23,993M, +5.9% (operations +6.0%); U.S. +9.1% to $14,959M, international +1.5% to $10,440M.
Innovative Medicine sales $16,757M, +7.7%; MedTech $8,642M, +2.5%, with MedTech international up just 0.1%.
GAAP net earnings fell 95.9% to $210M and diluted EPS 95.8% to $0.09, driven by $5,780M of other (income) expense, net vs $(478)M income a year ago.
Adjusted net earnings $6,339M (-6.8%) and adjusted diluted EPS $2.59 vs $2.80 (-7.5%); adjusted effective tax rate 17.4% vs 19.4%.
R&D expense rose 26.7% to $4,652M and IPR&D impairments were $339M; nine-month worldwide sales $74,771M, +7.4%.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.